MCID: RTN020
MIFTS: 45

Retinal Vascular Disease

Categories: Cardiovascular diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Retinal Vascular Disease

MalaCards integrated aliases for Retinal Vascular Disease:

Name: Retinal Vascular Disease 12 15
Retinal Vascular 54 70
Retina Circulation Disorder 12
Retinal Vascular Disorder 70

Classifications:



External Ids:

Disease Ontology 12 DOID:2462
NCIt 50 C35170
SNOMED-CT 67 57534004
UMLS 70 C0154833 C0549652

Summaries for Retinal Vascular Disease

MalaCards based summary : Retinal Vascular Disease, also known as retinal vascular, is related to vascular disease and exudative vitreoretinopathy 1, and has symptoms including chest pain An important gene associated with Retinal Vascular Disease is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are MicroRNAs in cancer and Selenium Micronutrient Network. The drugs Travoprost and Latanoprost have been mentioned in the context of this disorder. Affiliated tissues include endothelial, retina and eye, and related phenotypes are liver/biliary system and vision/eye

Related Diseases for Retinal Vascular Disease

Diseases related to Retinal Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 571)
# Related Disease Score Top Affiliating Genes
1 vascular disease 31.7 VEGFA PLG MTHFR MIR21 MIR126 INS
2 exudative vitreoretinopathy 1 31.5 VEGFA SERPINF1 NDP KDR INS CRYAA
3 central retinal artery occlusion 31.5 VEGFA PLG MTHFR CRYAA
4 retinal vein occlusion 31.3 VEGFA SERPINF1 MTHFR KDR
5 leukostasis 31.2 VEGFA SERPINF1 KDR
6 intraocular pressure quantitative trait locus 31.2 VEGFA SERPINF1 CRYAA CCN2
7 atherosclerosis susceptibility 31.0 VEGFA MTHFR INS ALB
8 open-angle glaucoma 31.0 VEGFA MTHFR CRYAA ALB
9 branch retinal artery occlusion 31.0 VEGFA PLG MTHFR CRYAA
10 retinal artery occlusion 30.9 VEGFA PLG MTHFR KDR CRYAA
11 diabetes mellitus 30.9 VEGFA MTHFR MIR20A MIR126 KDR INS
12 macular retinal edema 30.9 VEGFA SERPINF1 KDR INS CRYAA ALB
13 ischemia 30.9 VEGFA PLG MIR21 KDR
14 background diabetic retinopathy 30.8 VEGFA KDR INS ALB AKR1B1
15 sleep apnea 30.8 VEGFA INS ALB
16 type 1 diabetes mellitus 30.8 VEGFA MIR21 INS ALB AKR1B1
17 central retinal vein occlusion 30.8 VEGFA SERPINF1 MTHFR
18 rubeosis iridis 30.8 VEGFA PLG INS
19 endophthalmitis 30.8 VEGFA PLG CRYAA ALB
20 diabetic macular edema 30.7 VEGFA SERPINF1 AKR1B1
21 retinal disease 30.7 NDP H2AC18 CRYAA ALB AIPL1
22 macular holes 30.7 VEGFA SERPINF1 PLG CRYAA
23 corneal neovascularization 30.6 VEGFA SERPINF1 PLG KDR CRYAA
24 retinal vascular occlusion 30.6 VEGFA SERPINF1 PLG MTHFR KDR CRYAA
25 migraine with or without aura 1 30.6 PLG MTHFR INS H2AC18 ALB
26 kuhnt-junius degeneration 30.6 VEGFA SERPINF1 PLG MIR126 KDR CRYAA
27 pre-eclampsia 30.6 VEGFA MTHFR MIR126 KDR INS ALB
28 retinitis pigmentosa 30.6 VEGFA SERPINF1 LIF KDR INS H2AC18
29 type 2 diabetes mellitus 30.6 VEGFA MTHFR MIR126 KDR INS CCN2
30 diabetic neuropathy 30.6 VEGFA INS AKR1B1
31 retinal microaneurysm 30.5 VEGFA MIR20A INS AKR1B1
32 coats disease 30.5 VEGFA NDP KDR
33 neovascular glaucoma 30.5 VEGFA PLG KDR CRYAA
34 telangiectasis 30.5 VEGFA NDP H2AC18
35 polyneuropathy 30.5 VEGFA INS ALB AKR1B1
36 cataract 30.5 VEGFA SERPINF1 MTHFR INS CRYAA ALB
37 macular degeneration, age-related, 1 30.5 VEGFA SERPINF1 PLG KDR INS H2AC18
38 hypertension, essential 30.5 VEGFA PLG MTHFR MIR30A MIR21 MIR126
39 retinal detachment 30.5 VEGFA SERPINF1 NDP CCN2
40 microvascular complications of diabetes 1 30.4 VEGFA SERPINF1 KDR INS CRYAA CCN2
41 chronic kidney disease 30.4 VEGFA MTHFR MIR21 MIR126 INS CCN2
42 fundus dystrophy 30.4 VEGFA SERPINF1 KDR INS CRYAA ALB
43 heart disease 30.4 VEGFA MTHFR MIR21 MIR126 KDR INS
44 eclampsia 30.4 VEGFA MTHFR ALB
45 leber plus disease 30.4 VEGFA SERPINF1 INS CRYAA ALB AIPL1
46 microvascular complications of diabetes 5 30.3 VEGFA SERPINF1 PLG MIR30A MIR21 MIR20B
47 ischemic neuropathy 30.3 VEGFA NDP
48 apnea, obstructive sleep 30.3 VEGFA INS ALB
49 severe nonproliferative diabetic retinopathy 30.3 VEGFA INS ALB AKR1B1
50 proteinuria, chronic benign 30.3 VEGFA INS ALB

Graphical network of the top 20 diseases related to Retinal Vascular Disease:



Diseases related to Retinal Vascular Disease

Symptoms & Phenotypes for Retinal Vascular Disease

UMLS symptoms related to Retinal Vascular Disease:


chest pain

MGI Mouse Phenotypes related to Retinal Vascular Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.56 ALB CCN2 INS KDR LIF MTHFR
2 vision/eye MP:0005391 9.36 AIPL1 AKR1B1 CCN2 INS KDR LIF

Drugs & Therapeutics for Retinal Vascular Disease

Drugs for Retinal Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Travoprost Approved Phase 4 157283-68-6 5282226
2
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
3 Antihypertensive Agents Phase 4
4
Bevacizumab Approved, Investigational Phase 3 216974-75-3
5
Fasudil Investigational Phase 2, Phase 3 103745-39-7
6 Hormones Phase 2, Phase 3
7 Vasodilator Agents Phase 2, Phase 3
8 Pharmaceutical Solutions Phase 2, Phase 3
9 Ophthalmic Solutions Phase 2, Phase 3
10 Lubricant Eye Drops Phase 2, Phase 3
11 Protein Kinase Inhibitors Phase 2, Phase 3
12 Calcium, Dietary Phase 2, Phase 3
13 calcium channel blockers Phase 2, Phase 3
14
Calcium Nutraceutical Phase 2, Phase 3 7440-70-2 271
15
Propranolol Approved, Investigational Phase 2 525-66-6 4946
16
Isoproterenol Approved, Investigational Phase 2 7683-59-2 3779
17
Atropine Approved, Vet_approved Phase 2 5908-99-6, 51-55-8 174174
18
Betamethasone Approved, Vet_approved Phase 2 378-44-9 9782
19
Glucagon Approved Phase 2 16941-32-5
20
Ipratropium Approved, Experimental Phase 2 22254-24-6, 60205-81-4 43232 657309
21
Terlipressin Approved, Investigational Phase 2 14636-12-5 72081
22 Anesthetics Phase 2
23 Glucagon-Like Peptide 1 Phase 2
24 Albuterol Phase 2
25 Bromides Phase 2
26
Triamcinolone Approved, Vet_approved Phase 1 124-94-7 31307
27
Pimagedine Investigational Phase 1 79-17-4
28 Triamcinolone hexacetonide Phase 1
29 Triamcinolone diacetate Phase 1
30 Immunosuppressive Agents Phase 1
31 triamcinolone acetonide Phase 1
32 glucocorticoids Phase 1
33 Hormone Antagonists Phase 1
34 Anti-Inflammatory Agents Phase 1
35 Immunologic Factors Phase 1
36
Verteporfin Approved, Investigational 129497-78-5
37
Tocopherol Approved, Investigational 1406-66-2
38
Zinc Approved, Investigational 7440-66-6 32051
39
Dorzolamide Approved 120279-96-1 3154 5284549
40
Timolol Approved 26839-75-8 33624 5478
41
Nicotine Approved 54-11-5 942 89594
42
Sofosbuvir Approved 1190307-88-0 45375808
43
Vitamin C Approved, Nutraceutical 50-81-7 5785 54670067
44
Vitamin E Approved, Nutraceutical, Vet_approved 59-02-9 14985
45
Lutein Approved, Investigational, Nutraceutical 127-40-2 5281243
46 Tocotrienol Investigational 6829-55-6
47
Maleic acid Experimental 110-16-7 444266
48 Photosensitizing Agents
49 Dermatologic Agents
50 Mitogens

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
2 Influence of Travoprost 0.004% and Latanoprost 0.005% on Retinal Vascular Diameter and Choroidal Blood Flow in Glaucoma Patients Completed NCT00308945 Phase 4 travoprost 0.004% (drug);latanoprost 0.005% (drug)
3 Bevacizumab and Retinal Vascular Occlusions Unknown status NCT00347711 Phase 3 Intravitreal injection
4 Fasudil Eye Drop in Retinopathy Of Prematurity, Retinal Vascularization Induction and Disease Progression Inhibition, a Randomized Clinical Trial Recruiting NCT04191954 Phase 2, Phase 3 Fasudil eye drops (concentration 0.5 percent);receive artificial tears drop
5 Safety and Efficacy of Propranolol Treatment in Newborns With Retinopathy of Prematurity:a Prospective Cohort Study Unknown status NCT03038295 Phase 2 Propranolol;placebo
6 Pilot Study of Intravitreal Injection of Triamcinolone Acetonide Formulation for Retinal Vascular Disorders Completed NCT00071227 Phase 1 Triamcinolone Acetonide (TAC-PF)
7 Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients Completed NCT02099981 Phase 1 Aminoguanidine
8 Ocular Imaging Study Using Advanced OCT Unknown status NCT02827071
9 Indocyanine Green Angiography-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities. Unknown status NCT01974622 Visudyne
10 Obstructive Sleep Apnea, Retinal Vein Occlusion, Retinal Artery Occlusion Unknown status NCT01291862
11 Department of Neonatology, Children's Hospital of Zhengzhou Unknown status NCT02977000 Propranolol
12 Retinal Vascular Reactivity in Response to Isoxic Hypercapnia in Subjects With Newly Diagnosed Glaucoma Unknown status NCT01209975
13 Examination of the Body-fluid Balance in Patients With Retinal Vascular Occlusion Before and During Hemodilution and the Influence of Drinking Habits on the Degree of Body Hydration Unknown status NCT01939119
14 RETRO CRVO: Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion Completed NCT02645747 Aflibercept (Eylea, BAY86-5321)
15 Analysis of the Variation of the Retinal Vascularization After a Prolonged Effort Completed NCT03864380
16 Effect of Retaron® on Oxygen Induced Retinal Vasoconstriction in LPS Induced Inflammatory Model in Humans Completed NCT02221089 Escherichia coli Endotoxin
17 Evaluation of Heidelberg Engineering SPECTRALIS With OCT Angiography Module Completed NCT03279939
18 The Role of Quantitative Deep Capillary Plexus in the Pathogenesis of Retinal Angiomatous Proliferation: an Optical Coherence Tomography Angiography Study. Completed NCT04689789
19 Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG) Completed NCT00824824 Dorzolamide 2%-timolol 0.5%;Brimonidine 0.2%-0.5% timolol 0.5
20 Early Retinal Vascular Modifications After Endoscopic Endonasal Pituitary Surgery: The Role of OCT- Angiography Completed NCT04425954
21 CHAMPS Eye Study - Myopia and Retinal Vascular Geometry in Relation to Physical Activity. Completed NCT02346006
22 Retinal Vascular Features in Ocular Blunt Trauma by Optical Coherence Tomography Angiography Completed NCT04546997
23 Retinal Vascular Changes After Endoscopic Endonasal Pituitary Surgery During One Year's Follow up, by Optical Coherence Tomography Angiography Completed NCT04546386
24 Influence of Plasma Glucose Levels on Retinal Vascular Diameter and Choroidal Blood Flow in Vasospastic Subjects Completed NCT00350129
25 Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease Recruiting NCT04505618
26 Evaluation of Additional Heidelberg Engineering SPECTRALIS With OCT Angiography Module (OCTA Module) Scan Types Recruiting NCT04604002
27 Study of Retinal Vascular Parameters in Patients With Wilson's Disease Recruiting NCT04408300
28 Pilot Study: Retinal Vascular Network and Obstructive Sleep Apnea Recruiting NCT03979001
29 Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV) in Healthy Subject and Subject Affected by Glaucoma or Retinal Venous Occlusion Recruiting NCT03525132
30 Contraceptive Pills and Retinal Vascularization (Piluret) Recruiting NCT03964636
31 Impact of Nicotine on Retinal Vascularization (Tabaret) Recruiting NCT03964623
32 Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2, Using Novel Non-invasive Imaging Methods, in a Longitudinal, Prospective and Interventional Clinical Study With 2 Years of Duration (CORDIS) Active, not recruiting NCT03696810
33 Evaluation of Microvascular Changes in the Perifoveal Vascular Network Using Optical Coherence Tomography Angiography (OCT-A) in Type I Diabetes Mellitus Active, not recruiting NCT03422965
34 Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir (Sovaldi) in Patients With Hepatitis C Virus Infection Active, not recruiting NCT04159246 Sofosbuvir (Sovaldi)
35 Normative Data Collection Study of the Zilia Ocular for the Measurement of Oxygen Saturation in the Retina Not yet recruiting NCT04408677
36 Physiologic Change of Posterior Ocular Segment During Pregnancy Not yet recruiting NCT04731415
37 Physiologic Changes of Posterior Ocular Segment During the Menstrual Cycle Not yet recruiting NCT04731207
38 Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging Terminated NCT01834196
39 Evaluation of the Repeatability and Reproducibility of OCTA Image Quality With the Heidelberg Engineering SPECTRALIS With OCT Angiography Module Terminated NCT03530449

Search NIH Clinical Center for Retinal Vascular Disease

Genetic Tests for Retinal Vascular Disease

Anatomical Context for Retinal Vascular Disease

MalaCards organs/tissues related to Retinal Vascular Disease:

40
Endothelial, Retina, Eye, Heart, Kidney, Pituitary, Bone

Publications for Retinal Vascular Disease

Articles related to Retinal Vascular Disease:

(show top 50) (show all 4858)
# Title Authors PMID Year
1
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. 61 54
20232317 2010
2
The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model. 54 61
19639355 2010
3
Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum. 61 54
19916212 2009
4
Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. 61 54
19646547 2009
5
Risk factors and growth factors in ROP. 54 61
19828269 2009
6
Kallidinogenase normalizes retinal vasopermeability in streptozotocin-induced diabetic rats: potential roles of vascular endothelial growth factor and nitric oxide. 61 54
19374851 2009
7
Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy. 61 54
19107135 2009
8
Feedback mechanism between blood vessels and astrocytes in retinal vascular development. 54 61
19577710 2009
9
Association of vitreous inflammatory factors with diabetic macular edema. 61 54
19118698 2009
10
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. 54 61
18483622 2008
11
VEGF-induced choroidal damage in a murine model of retinal neovascularisation. 61 54
18523088 2008
12
Aquaporin 1 is required for hypoxia-inducible angiogenesis in human retinal vascular endothelial cells. 61 54
18275976 2008
13
Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. 61 54
17420693 2007
14
Vascular endothelial growth factor C promotes survival of retinal vascular endothelial cells via vascular endothelial growth factor receptor-2. 61 54
16943230 2007
15
Molecular targets for retinal vascular diseases. 54 61
17133346 2007
16
Age-dependent retinal capillary pericyte degeneration in galactose-fed dogs. 54 61
17341153 2007
17
Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. 61 54
17293777 2007
18
Retinopathy of prematurity. 61 54
17332988 2007
19
Exogenous leukemia inhibitory factor (LIF) attenuates retinal vascularization reducing cell proliferation not apoptosis. 61 54
16643897 2006
20
Hepatocyte growth factor induces retinal vascular permeability via MAP-kinase and PI-3 kinase without altering retinal hemodynamics. 61 54
16723489 2006
21
Therapeutic potential of angiostatin in diabetic nephropathy. 54 61
16394111 2006
22
Role of the Norrie disease pseudoglioma gene in sprouting angiogenesis during development of the retinal vasculature. 54 61
16123442 2005
23
Predominant rod photoreceptor degeneration in Leber congenital amaurosis. 54 61
16052170 2005
24
Angiopoietin concentrations in diabetic retinopathy. 54 61
15774928 2005
25
Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina. 61 54
15258030 2004
26
VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. 61 54
15303088 2004
27
Pathogenesis of retinopathy of prematurity. 61 54
15135797 2004
28
VEGF and KDR gene expression during human embryonic and fetal eye development. 61 54
14691147 2004
29
An unusual retinal vascular morphology in connection with a novel AIPL1 mutation in Leber's congenital amaurosis. 61 54
12881340 2003
30
Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. 61 54
12652648 2003
31
von Hippel-Lindau disease type 2A in a family with a duplicated 21-base-pair in-frame insertion mutation in the VHL gene. 61 54
12644949 2003
32
Pigment epithelium-derived factor expression in the developing mouse eye. 61 54
12447163 2002
33
Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. 54 61
11596663 2001
34
Role of VEGF-A in endothelial phenotypic shift in human diabetic retinopathy and VEGF-A-induced retinopathy in monkeys. 61 54
11340407 2001
35
Role of vascular endothelial growth factor in diabetic vascular complications. 61 54
10997700 2000
36
[Cell biology of intraocular vascular diseases]. 61 54
10643294 1999
37
VEGF increases retinal vascular ICAM-1 expression in vivo. 61 54
10393052 1999
38
Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. 61 54
10211121 1998
39
Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. 61 54
9287049 1997
40
Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. 54 61
9227268 1997
41
Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. 61 54
9008628 1997
42
Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. 61 54
9046048 1997
43
Vascular endothelial growth factor--its role in retinal vascular proliferation. 54 61
7526213 1994
44
Oxidative stress induces adult T cell leukemia derived factor/thioredoxin in the rat retina. 54 61
8139268 1994
45
Electron microscopic immunocytochemical demonstration of blood-retinal barrier breakdown in human diabetics and its association with aldose reductase in retinal vascular endothelium and retinal pigment epithelium. 54 61
8226103 1993
46
Characterization of galactose-containing glycoconjugates in the human retina: a lectin histochemical study. 54 61
2091899 1990
47
The role of gap junctions in cell death and neuromodulation in the retina. 61
33642359 2021
48
G-protein-coupled estrogen receptor protects retinal ganglion cells via inhibiting endoplasmic reticulum stress under hyperoxia. 61
33151568 2021
49
Drug-related adverse effects of antivascular endothelial growth factor agents. 61
33770015 2021
50
Automated diagnoses of age-related macular degeneration and polypoidal choroidal vasculopathy using bi-modal deep convolutional neural networks. 61
32499330 2021

Variations for Retinal Vascular Disease

Expression for Retinal Vascular Disease

Search GEO for disease gene expression data for Retinal Vascular Disease.

Pathways for Retinal Vascular Disease

GO Terms for Retinal Vascular Disease

Cellular components related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 VEGFA SERPINF1 PLG NDP LIF KDR
2 extracellular space GO:0005615 9.5 VEGFA SERPINF1 PLG NDP MIR30A MIR21
3 extracellular vesicle GO:1903561 9.35 MIR30A MIR21 MIR20B MIR20A MIR126
4 platelet alpha granule lumen GO:0031093 9.33 VEGFA PLG ALB

Biological processes related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 10 MIR30A MIR21 MIR20B MIR20A MIR146B MIR126
2 positive regulation of cell proliferation GO:0008284 9.95 VEGFA MIR21 LIF KDR INS CCN2
3 positive regulation of gene expression GO:0010628 9.93 VEGFA MIR21 MIR20B LIF INS CCN2
4 positive regulation of cell migration GO:0030335 9.91 VEGFA MIR21 KDR INS
5 negative regulation of apoptotic process GO:0043066 9.91 VEGFA MIR21 KDR CRYAA ALB AKR1B1
6 positive regulation of protein phosphorylation GO:0001934 9.87 VEGFA MIR21 KDR CCN2
7 positive regulation of protein kinase B signaling GO:0051897 9.86 VEGFA MIR21 MIR126 INS
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 VEGFA MIR21 MIR126 KDR CCN2
9 negative regulation of gene expression GO:0010629 9.8 VEGFA SERPINF1 MIR21 MIR20A KDR CCN2
10 lung development GO:0030324 9.79 VEGFA LIF CCN2
11 positive regulation of osteoblast differentiation GO:0045669 9.77 MIR21 MIR20B MIR20A
12 positive regulation of endothelial cell migration GO:0010595 9.76 VEGFA MIR21 KDR
13 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.69 VEGFA MIR126 KDR
14 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.67 VEGFA MIR20A KDR
15 positive regulation of positive chemotaxis GO:0050927 9.61 VEGFA KDR
16 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.61 VEGFA MIR21 MIR126
17 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.6 VEGFA PLG
18 vascular wound healing GO:0061042 9.58 VEGFA KDR
19 positive regulation of blood vessel endothelial cell migration GO:0043536 9.56 VEGFA MIR30A MIR126 KDR
20 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.55 VEGFA KDR
21 positive regulation of MAPK cascade GO:0043410 9.55 VEGFA MIR126 LIF KDR INS
22 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.54 VEGFA KDR
23 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.35 VEGFA MIR21 MIR126 KDR INS
24 positive regulation of angiogenesis GO:0045766 9.1 VEGFA MIR30A MIR21 MIR20A MIR126 KDR

Molecular functions related to Retinal Vascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.35 MIR30A MIR21 MIR20B MIR20A MIR126
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR30A MIR21 MIR20B MIR20A MIR146B MIR126

Sources for Retinal Vascular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....